Fibroplate Inc Profile last edited on: 8/21/2020
CAGE: 6XDJ6
UEI: UKBYP1UTHBK1
Business Identifier: Tackling remediation of skin injury in cancer patients due to radiation therapy 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
6280 South Valley View Boulevard Suite 104
Las Vegas, NV 89118
Las Vegas, NV 89118
| (714) 914-2340 |
| info@fibroplate.com |
| www.fibroplate.com |
Location: Single
Congr. District: 03
County: Clark
Congr. District: 03
County: Clark
Public Profile
Organized around addressing radiation induced injury suffered by patients after they have undergone radiation therapy, Fibroplate, Inc. (FB) is an early stage biopharmaceutical company working on the first-in-class fibrinogen-coated albumin nanosphere (FAS). The technology has been shown to offer the potential to improve the conditions of many patients with serous medical conditions. Of particular focus are cancer patients who have received radiation therapy and who suffer from the effects of high dose irradiation. The product is a ready-to-use suspension of biocompatible protein nanospheres which works immediately after intravenous administration to patients, resulting in the mitigation and therapeutic treatment of radiation harm
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 1 | NIH | $253,688 | |
| Project Title: A novel agent to manage thrombocytopenic patients with platelet transfusion refractoriness | ||||
| 2021 | 1 | NIH | $246,634 | |
| Project Title: Fibrinogen coated albumin spheres to accelerate bone healing in older adults. | ||||
| 2021 | 2 | NIH | $1,992,194 | |
| Project Title: A Multivalent, Easy-To-Use Product to Mitigate and Treat Radiation Exposure | ||||
| 0 | 1 | NIH | $386,470 | |
| Project Title: Fibrinogen-coated albumin nanospheres for mitigation of irradiation-induced wound healing impairment in breast cancer patients. | ||||
Key People / Management
Richard Yen -- President
Sarah Weidner
Franny Yen
Sarah Weidner
Franny Yen
Company News
There are no news available.
